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Exemption (IDE) study and Micra Post-Approval Registry (PAR)
demonstrated excellent safety and efﬁcacy performance; however,
intermediate-term results across a large patient population in the
real-world setting have not been evaluated.
OBJECTIVES We report updated performance of the Micra trans-
catheter pacemaker from a worldwide PAR and compare it with
the IDE study as well as a transvenous historical control.
METHODS The safety objective of the analysis was system- or
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months. Through 12 months, the major complication rate was
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El-Chami et al Micra Updated Real-World Performance 1801major complication rate trended lower in the PAR than in the IDE
study (hazard ratio 0.71; 95% CI 0.44–1.1; P 5 .160), driven by
the lower pericardial effusion rate in the PAR. There were 3 cases
of infection associated with the procedure, but none required de-
vice removal and there were no battery or telemetry issues. Pacing
thresholds were low and stable through 12 months postimplanta-
tion.
CONCLUSION Performance of the Micra transcatheter pace-
maker in international clinical practice remains consistent
with previously reported data. Major complications were infre-
quent and occurred 63% less often compared to transvenous
systems.CLINICAL TRIAL REGISTRATION Micra Transcatheter Pacing
System Post-Approval Registry ClinicalTrials.gov identiﬁer:
NCT02536118; Micra Transcatheter Pacing Study ClinicalTrials.gov
identiﬁer: NCT02004873.KEYWORDS Leadless pacing; Real-world performance; Transcath-
eter pacemaker; Updated results; Transvenous pacemaker(Heart Rhythm 2018;15:1800–1807) © 2018 The Authors. Pub-
lished by Elsevier Inc. on behalf of Heart Rhythm Society. This is
an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Transvenous pacing leads and subcutaneous pockets are
frequently the source of complications with traditional trans-
venous pacemakers (TV-PPMs).1,2 Leadless pacemakers
were designed to minimize these complications.3,4 The
Micra Investigational Device Exemption (IDE) study
established the safety and efﬁcacy of the Micra
transcatheter pacing system (TPS).4 In the IDE study, the Mi-
cra TPS was successfully implanted in 99.2% of patients with
a low rate of complications at 1-year follow-up (4%), which
was 48% lower than that for patients with transvenous sys-
tems.5 Remarkably, no infections or macro-dislodgments
were encountered in this study. Pacing parameters remained
excellent and stable through 24-month follow-up. While
these early results were encouraging, it is not clear that the
efﬁcacy and safety are similar outside the conﬁnes of a clin-
ical trial conducted at major pacing centers.
The Micra Post-Approval Registry (PAR), mandated by
the Food and Drug Administration, was designed to study
the safety and efﬁcacy of this device in a real-world setting.6
In this article, we report updated performance of the Micra
TPS from a worldwide PAR and compare it with the IDE
study as well as a transvenous historical control.Methods
Study design
The design of theMicra PAR has been described previously.6
Brieﬂy, the aim of this active, prospective, nonrandomized,
multicenter registry was to further evaluate short- and long-
term safety performance of the Micra TPS when used as in-
tended in “real-world” clinical practice after commercial
release. The protocol was approved by an ethics committee
at each of the participating centers, as applicable. All system-
and procedure-related adverse events were adjudicated by a
Clinical Events Committee of independent physicians.Patients and procedures
All patients intended to be implanted with a market-approved
Micra device at participating centers were eligible. Enrolled
patients provided written informed consent. Patients who
participated in a premarket trial (ie, IDE study) and consented
to participate in the PAR for long-term follow-up wereexcluded from this analysis. The ﬁrst new registry enrollment
occurred on July 26, 2015, after regulatory approval of the
Micra device in Europe, and global enrollment was closed
on March 2, 2018. The required 9-year registry follow-up
period is ongoing.
The Micra TPS is a single-chamber ventricular pacemaker
and is 93% smaller than a TV-PPM system with a total vol-
ume of 0.8 mL. The device has similar functionality and fea-
tures to existing single-chamber ventricular pacemakers,
including rate adaptive pacing, remote monitoring capabil-
ities, and automated pacing capture threshold management,
designed to maximize battery longevity. Micra is inherently
magnetic resonance imaging conditionally safe for full-
body scans in both 1.5-T and 3-T scanners.7 The device is im-
planted directly in the right ventricle through a femoral vein.
The device is ﬁxated in the myocardium via 4 ﬂexible nitinol
tines.8,9
Enrolled patients underwent implant attempt and are fol-
lowed according to routine care practices of their provider.
Patient and device status are reported at implant/prehospital
discharge, 30 days postimplantation, and at least annually
thereafter for a minimum follow-up period of 9 years. All sys-
tem- and procedure-related adverse events or system revi-
sions (eg, device extraction) are to be reported immediately
after center awareness.End points
The aim of this analysis was to assess system- or procedure-
related major complications through 12 months postimplan-
tation. Adopting the same criteria used in the Micra IDE
study, major complications were deﬁned as system- and
procedure-related events resulting in death, permanent loss
of device function, hospitalization, prolonged hospitalization
by 48 hours, or system revision. The diagnoses of all events
and any resulting clinical actions were reported by center in-
vestigators. The Clinical Events Committee reviewed and
adjudicated, at a minimum, all system- and procedure-
related adverse events to determine relatedness and whether
the events met the criterion of a major complication. Major
complication rates through 12 months were compared with
those previously reported in the IDE study.5 In addition,
for a comparison of safety performance relative to
Table 1 Baseline characteristics
Characteristic Postmarket (n 5 1817) IDE (n 5 726) Total (N 5 2543 ) P
Sex: male 1111 (61.1) 427 (58.8) 1538 (60.5) .26
Atrial arrhythmia 1370 (75.4) 548 (75.5) 1918 (75.4) ..99
CHF 234 (12.9) 131 (18.0) 365 (14.4) .001
COPD 176 (9.7) 92 (12.7) 268 (10.5) .032
CAD 402 (22.1) 205 (28.2) 607 (23.9) .001
HTN 1165 (64.1) 571 (78.7) 1736 (68.3) ,.001
Diabetes 480 (26.4) 207 (28.5) 687 (27.0) .30
Prior CIED 265 (14.6) 0 (0.0) 265 (10.4) ,.001
Condition that precludes the use of a TV-PPM 435 (23.9) 45 (6.2) 480 (18.9) ,.001
Pacing indication
Bradyarrhythmia with AF 1127 (62.0) 464 (63.9) 1591 (62.6) ,.001
Sinus node dysfunction 177 (9.7) 126 (17.4) 303 (11.9)
AV block 211 (11.6) 109 (15.0) 320 (12.6)
Syncope 243 (13.4) 16 (2.2) 259 (10.2)
Other 50 (2.8) 11 (1.5) 61 (2.4)
Not reported 9 (0.5) 0 (0.0) 9 (0.4)
Values are presented as n (%).
AF5 atrial ﬁbrillation; AV5 atrioventricular; CAD5 coronary artery disease; CHF5congestive heart failure; CIED5 cardiac implantable electronic device;
COPD 5 chronic obstructive pulmonary disease; HTN 5hypertension; IDE 5 Micra Investigational Device Exemption; TV-PPM 5 transvenous pacemaker.
1802 Heart Rhythm, Vol 15, No 12, December 2018conventional pacemaker systems with transvenous leads, a
data set of 2667 patients with de novo pacemakers from 6
recent Medtronic trials of dual-chamber pacing was assem-
bled.4 Events related only to the right atrial lead were
excluded in order to approximate a single-chamber data set.
Rates of major complications, including breakdown of major
complication criteria, were compared between the Micra and
transvenous control groups. Electrical performance at im-
plantation/prehospital discharge and follow-up was also
characterized.Statistical analysis
At the time of the database freeze for this analysis, all but 6
successfully implanted patients were included because of
delayed data entry. Summary statistics were obtained and
reported using mean 6 SD for continuous variables and fre-
quency and percentage for categorical variables.
The major complication rate was calculated for each cate-
gory and subcategory for both acute major complication
(30 days of follow-up) and chronic major complication
(.30 days of follow-up). The distribution of pacing percent-
age for Micra patients at the last follow-up visit was plotted.
Battery longevity estimates were obtained from each
patient’s last device interrogation and normalized to the
longevity remaining at 6 months (183 days) postimplanta-
tion. Kaplan-Meier methods were used to estimate the rate
of major complication (and its components) at 12 months
postimplantation. In addition, the Fine-Gray competing risk
model was used to compare the risk of major complications
(and its components) through 12 months between 2 groups:
2667 patients in the transvenous control group vs 1817
patients with an attempted Micra implantation procedure in
the postmarket population and 726 patients with an attempted
Micra implantation procedure in the IDE study. However,
when comparing components of the major complicationrate, the Fisher exact test was used if zero events were
observed for one of the groups. All analyses were performed
with SAS version 9.4 (SAS Institute Inc., Cary, NC) or the R
statistical package (R Project for Statistical Computing,
Vienna, Austria). Electrical parameters were summarized at
each study visit using means and SDs.Results
Patients
A total of 1817 enrolled patients underwent implant attempt
from 179 centers in 23 countries from July 2015 through
March 2018. Patients were on average 75.6 6 13.5 years of
age, were mostly (n51111, 61.1%) men, and had multiple co-
morbidities, including hypertension (n51165, 64.1%), dia-
betes (n5480, 26.4%), coronary artery disease (n5402,
22.1%), and chronic obstructive pulmonary disease (COPD)
(n5176, 9.7%) (Table 1). Compared with patients in the
IDE study, patients in the PAR had fewer comorbidities,
including coronary artery disease, heart failure, and COPD.
Nearly a quarter of patients (n5435, 23.9%) had a condition
the implanting physician felt precluded the use of a
transvenous system and 265 (14.6%) had a prior cardiac
implantable electronic device implanted. The most common
primary indication for pacing was bradyarrhythmia with atrial
ﬁbrillation (AF) (n51127, 62.0%), followed by syncope
(n5243, 13.4%), atrioventricular (AV) block (n5211,
11.6%), sinus node dysfunction (n5177, 9.7%), and other/
not reported (n559, 3.3%). Patients in the PAR tended to be
older, were more likely to be male, and had a higher incidence
of diabetes, COPD, and AF than did the historical TV-PPM
cohort (Supplemental Table 1). TheMicra device was success-
fully implanted in 1801 patients (99.1%). Devices were pre-
dominantly placed in the right ventricular (RV) septum
(n51156, 63.6%), followed by the RV apex (n5582,
32.0%). The median procedure time (time from the introducer
Table 2 Major complications for patients with an attempted Micra implantation procedure (n51817)
Complication
No. of events (no. of patients, percentage)
30 d .30 d Total major complications
Total major complications 41 (36, 1.98) 5 (5, 0.28) 46 (41, 2.26)
Embolism and thrombosis 2 (2, 0.11) 0 (0, 0) 2 (2, 0.11)
Deep vein thrombosis 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Pulmonary embolism 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Events at the groin puncture site 10 (10, 0.55) 1 (1, 0.06) 11 (11, 0.61)
Arterial injury/atrioventricular ﬁstula 6 (6, 0.33) 1 (1, 0.06) 7 (7, 0.39)
Hematoma 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Incision site hemorrhage 2 (2, 0.11) 0 (0, 0) 2 (2, 0.11)
Retroperitoneal hemorrhage 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Cardiac effusion/perforation 8 (8, 0.44) 0 (0, 0) 8 (8, 0.44)
Pacing issues 12 (11, 0.61) 2 (2, 0.11) 14 (13, 0.72)
Device capturing issue/elevated thresholds 9 (9, 0.50) 2 (2, 0.11) 11 (11, 0.61)
Device dislodgment 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Device embolization during an implant attempt 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Undersensing 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Infection 3 (3, 0.17) 0 (0, 0) 3 (3, 0.17)
Abdominal wall infection 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Hematoma infection 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Sepsis 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Other 6 (6, 0.33) 2 (2, 0.11) 8 (8, 0.44)
Blood pressure decreased 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Cardiac failure 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Cardiomyopathy 0 (0, 0) 1 (1, 0.06) 1 (1, 0.06)
Complication of device removal 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Noncardiac chest pain 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Pacemaker syndrome 0 (0, 0) 1 (1, 0.06) 1 (1, 0.06)
Pulmonary edema 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
Syncope 1 (1, 0.06) 0 (0, 0) 1 (1, 0.06)
El-Chami et al Micra Updated Real-World Performance 1803in to the introducer out) was 26.0 minutes (interquartile range
[IQR] 19–40 minutes), and the majority of implants (n51522,
83.8%) required 3 deployments. The mean follow-up dura-
tion was 6.86 6.9 months (range 0–30 months), with 465 pa-
tients having at least 12 months of follow-up.Safety
There were 46 major complications in 41 patients adjudicated
as related to the Micra device or procedure (Table 2). The
majority of major complications (89%) occurred within 30
days of implantation, with only 1 major complication
reported .6 months postimplantation. Of the major compli-
cations, there were 14 device pacing issue events, 11 events
at the groin puncture site, 8 cardiac effusion/perforation
events, 3 infection events, and 8 other events (including 1
cardiac failure event, 1 cardiomyopathy event, and 1 pace-
maker syndrome event).
One patient experienced a right groin hematoma infection
that occurred after a Micra/AV nodal ablation concomitant
procedure. The infection resolved with intravenous antibi-
otics. One patient underwent a percutaneous retrieval attempt
on the day of implantation owing to elevated thresholds. Dur-
ing the retrieval, the device became entangled in the patient’s
inferior vena cava ﬁlter (a contraindication for Micra implan-
tation), causing vascular trauma, which required surgical
repair. A second Micra device was successfully implantedthe same day. This patient experienced an abdominal wall
infection 25 days postimplantation, was hospitalized, treated
with intravenous antibiotics, and was discharged when the
infection resolved 5 days later. The third infection event
(sepsis, which resolved with antibiotics and did not require
device removal) was previously described.6
There was 1 dislodgment without embolization. The
device was attached to the RV myocardium in proximity to
the papillary muscle. This device was retrieved and reim-
planted 50 days after the original implantation procedure.
Another device embolized during implantation, and it was
snared and retrieved. This patient received another Micra
device during the same procedure.
One pacemaker syndrome event occurred 186 days post-
implantation. This patient underwent an upgrade to a cardiac
resynchronization therapy device.
Major complication criteria were not mutually exclusive,
and of the 46 events, 33 led to prolonged hospitalization by
48 hours, 17 led to hospitalization, 5 resulted in death, and
15 resulted in a system revision (Table 3). A subset of the
system revisions (9 events) were associated with loss of de-
vice function due to high pacing thresholds or failure of the
device to capture, resulting in the device being programmed
to OOO mode or retrieved and replaced with a new Micra
device or a transvenous device. Importantly, there were
no unexpected device issues, no telemetry failures, and no
battery issues.
Table 3 System- or procedure-related major complication breakdown for Micra and transvenous control patients
Major complication
criterion
Micra (n 5 1817)
Transvenous historical control
(n 5 2667)
No. of events
(no. of patients,
percentage)
12-mo KM
estimates
(95% CI) (%)
No. of events
(no. of patients,
percentage)
12-mo KM
estimates
(95% CI) (%)
Relative risk
reduction
(95% CI) (%) P
Total major complications 46 (41, 2.26) 2.7 (2.0 to 3.7) 230 (196, 7.35) 7.6 (6.6 to 8.7) 63 (48 to 73) ,.0001
Death 5 (5, 0.28) 0.3 (0.1 to 0.8) 0 (0, 0.00) 0.0 NE .0109
Hospitalization 17 (16, 0.88) 1.3 (0.8 to 2.1) 124 (106, 3.97) 4.1 (3.4 to 5.0) 71 (51 to 83) ,.0001
Prolonged hospitalization 33 (29, 1.60) 1.9 (1.3 to 2.7) 68 (64, 2.40) 2.4 (1.9 to 3.1) 24 (218 to 51) .2278
System revision 15 (13, 0.72) 0.9 (0.5 to 1.6) 102 (95, 3.56) 3.8 (3.1 to 4.6) 74 (54 to 85) ,.0001
Loss of device function 9 (9, 0.50) 0.7 (0.4 to 1.3) 0 (0, 0.00) 0.0 NE .0003
Major complication end point criteria are not mutually exclusive. For example, an event resulting in a system revision may also result in hospitalization.
CI 5 conﬁdence interval; KM 5 Kaplan-Meier; NE 5 not estimable.
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There were a total of 14 perforation/effusion events, and of
these, 8 met the criteria for a major complication. Of the 14
perforation/effusion events, 8 required pericardiocentesis, 4
required no intervention, and 2 required surgical repair and
ultimately led to death. The 6 perforation/effusion events
that did not meet the major complication criteria resolved
and did not lead to any long-term adverse events. The 2
perforation/effusion deaths were adjudicated as related to
the implantation procedure and not to the Micra device.
One patient was a 65-year-old woman with a low body
mass index (BMI) (17.4 kg/m2), hypertension, and renal
dysfunction requiring dialysis. After multiple attempts to
deploy the Micra device without successfully engaging the
tines, an echocardiogram revealed pericardial effusion. An
RV perforation was repaired surgically, but the patient expe-
rienced extensive blood loss and was pronounced dead the
same day despite administration of blood products. The
second patient was a 76-year-old woman with hypertension,
diabetes, and renal dysfunction requiring dialysis. The
implant attempt was unsuccessful because of tamponade
that required surgical repair. This patient had a complicated
postoperative course and developed sepsis 2 weeks later
with documented bacteremia and died w3 weeks after the
implant attempt owing to septic shock.
Previously reported risk factors for perforation/effusion
with Micra include BMI ,20 kg/m2, advanced age (85
years), female sex, congestive heart failure, non-AF indica-
tion, and chronic lung disease.10 Of the 14 patients with perfo-
ration/effusion events, 6 had .2 risk factors, 7 had 1–2 risk
factors, and 1 had 0 risk factors.Deaths
There were a total of 144 patient deaths reported in the PAR
due to any cause, of which 13 were due to sudden cardiac
death, 35 were due to nonsudden cardiac death, 77 were
due to noncardiac death, and 19 were for unknown reasons.
Three deaths were adjudicated as unknown relatedness to
the procedure, and 5 deaths were adjudicated as related to
the implantation procedure. One procedure-related death
was previously published. In brief, this patient died ofpulmonary edema in the setting of severe aortic valve disease
the day after his procedure.6 Two perforation-related deaths
were described in detail above. The fourth patient with a
procedure-related death was a 92-year-old woman with a
low BMI (19.2 kg/m2), hypertension, persistent AF, and
COPD who underwent concomitant Micra implantation and
AV node ablation. After the implantation procedure, a
computed tomography scan revealed retroperitoneal bleeding
and the patient’s condition worsened despite blood transfu-
sions and multiple rounds of epinephrine. The patient died
the next day. The ﬁfth procedure–related death involved an
84-year-old female patient on dialysis who was initially
admitted to the hospital for scheduled brachiocephalic arte-
riovenous ﬁstula creation. The patient experienced multiple
episodes of AF with rapid ventricular response in the next
2 weeks and was consulted for Micra placement. During
the implantation procedure, the patient became hypotensive
and died the next day. There was no evidence of pericardial
effusion or retroperitoneal bleeding, and the death was pre-
sumed to be due to RV failure, possibly from acute infarct.
Of the 3 patients with deaths adjudicated as unknown relat-
edness to the procedure, the ﬁrst patient was a 94-year-old
man who died at home 22 days postimplantation. The cause
of death was labeled as heart failure and was adjudicated as
unknown relatedness to the implantation procedure. The sec-
ond patient with a death adjudicated as unknown relatedness
to the procedure was a 74-year-old man who died after being
hospitalized with fever 25 days postimplantation and was
found dead in the hospital. The third patient was an
86-year-old man who presented to the hospital with cardiac
arrest 6 days postimplantation. The patient had ventricular
ﬁbrillation arrest and was shocked 6 times from an external
deﬁbrillator. This patient also had a history of heart failure.
Electrical performance
The mean pacing capture threshold was 0.66 0.55 V at 0.24
ms (n5 1661) at implantation and remained stable through 18
months of follow-up (0.666 0.45 V) (n5 202) (Figure 1). Of
the 566 patients with available pacing threshold data at 12
months, 97.0% had a pacing threshold of ,2 V. The mean
impedance was 730 6 181 U at implantation and 568 6
104 U at 18 months. The mean R-wave amplitude was
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Figure 1 Electrical performance over time. A: Pacing capture thresholds.
B: Impedance.C: Sensing. The vertical solid lines represent the SD. n values
represent the number of patients with data available at each time point.
El-Chami et al Micra Updated Real-World Performance 180511.1 6 5.2 mV at implantation and 13.0 6 5.9 mV at 18
months. For the 713 patients with device interrogation data
available, the median ventricular pacing percentage was
55.7% (IQR 7%–98%) (Figure 2) at the last follow-up visit.
Of these 713 patients, 45.3% were programmed to rate-
adaptive pacing and the lower pacing rate interval was 40,
.40–60, or .60 beats/min for 10.5%, 68.0%, and 21.5%
of patients, respectively. For the 451 patients with availableFigure 2 Ventricular pacing percentage obtained from the device memory
at each patient’s last follow-up visit for patients with at least 30 days of
follow-up. IQR 5 interquartile range.data at 6 months postimplantation, median battery longevity
was estimated to be 13.6 years (IQR 11.9–15.4 years).Safety: PAR cohort vs IDE and transvenous cohorts
Through 12months postimplantation, themajor complication
rate in the Micra PAR cohort was 2.7% (95% conﬁdence in-
terval [CI] 2.0%–3.7%) as compared with 7.6% (95% CI
6.6%–8.7%) in the historical TV-PPM cohort. This represents
a 63% lower risk of major complications (hazard ratio 0.37;
95%CI 0.27–0.52;P, .001). The reduction inmajor compli-
cations was primarily driven by a signiﬁcant 74% relative risk
reduction in system revisions and 71% relative risk reduction
in hospitalizations (Table 3). The major complication rate
trended lower in theMicra PAR than in the IDE study (hazard
ratio 0.71; 95% CI 0.44–1.1; P5 .160) (Figure 3). This was
driven by signiﬁcantly lower pericardial effusion rates in the
PAR (0.44% vs 1.52%; P 5 .009).Discussion
This is the largest report on leadless pacemakers to date.
More than 1800 patients were enrolled and followed over a
mean of w7 months, with .450 patients followed beyond
1 year. The results as detailed above show an excellent
implant success rate (99.1%), stable pacing parameters, and
reliable battery performance over the duration of follow-up.
The rate of procedure-related infections was low. Most
importantly, the 3 infections (an abdominal wall infection,
an infected groin hematoma, and sepsis) responded to antibi-
otics and did not require device removal. This low rate of
infection may be related to the absence of a subcutaneous
pocket and hence a lower likelihood of bacterial translocation
into the pacemaker site, in addition to the small surface area
of leadless pacemakers relative to transvenous leads, and
their tendency for encapsulation,11 which could make bacte-
rial adherence to the device less likely. Given the absence of
infections requiring device removal across all leadless pacing
data sets, more work to understand the clinical mechanisms
for this observation is warranted.3–5
In addition, the rate of dislodgments was low and seen
only in 1 patient (0.06%). This is conceivably a major advan-
tage of the Micra TPS over the TV-PPM and appears to be a
consistent ﬁnding. For instance, no dislodgments were
reported in the Micra IDE study. In contrast, the rate of trans-
venous lead dislodgments was reported in 3.3% of patients
within 2 months of implantation in the FOLLOWPACE
study and in 1.2% of patients implanted with a single-lead
pacemaker in the Danish registry.12
The rate of groin complications was low (0.61%), a
ﬁnding consistent with the groin complication rate (0.7%)
of the IDE study. This is a surprising, but reassuring, ﬁnding
given the large caliber Micra introducer sheath (23 F). While
the groin complication rate was low in the registry, a 92-year-
old patient with a low BMI developed retroperitoneal
bleeding, which eventually led to death. This highlights the
importance of careful groin access and consideration of
vascular ultrasound guidance for venous puncture, especially
Figure 3 Major complication rates through 24 months postimplantation for Micra PAR,Micra IDE study, and transvenous reference cohorts. Subdistributional
hazard ratio derived from data through 365 days postimplantation for each cohort by comparing the cumulative incidence functions given to the left of the dashed
line. CI 5 conﬁdence interval; HR 5 hazard ratio; IDE 5 Micra Investigational Device Exemption; PAR 5 Post-Approval Registry.
1806 Heart Rhythm, Vol 15, No 12, December 2018when dealing with octo- or nonagenarians, a population at
increased risk of groin complications.
An important ﬁnding of the PAR is the signiﬁcantly lower
rate of perforation (0.77% total and 0.44% meeting the crite-
rion for a major complication deﬁnition) as compared with
the original Micra IDE study data (1.8% total and 1.5%
meeting the criterion for a major complication deﬁnition).
This possibly reﬂects the rigorous training programs that
new implanters are exposed to. A major focus on implanting
these devices in the septum and on the use of intravenous
contrast with orthogonal radiographic views to conﬁrm the
position of the delivery system could explain the lower rate
of perforation. As mentioned above,w64% of Micra devices
were positioned in the septum in the PAR as compared with
33% in the IDE study. This rate of perforation is comparable
with the rate of perforation seen with the TV-PPM as reported
in a meta-analysis of 28 studies reporting on lead perforation.
In this meta-analysis, the mean rate of perforation with the
TV-PPM was 0.8%.12
In this study, a total of 14 pericardial effusions were re-
ported. Ten required an intervention (8 pericardiocentesis
and 2 surgical repair), while 4 were small effusions that did
not require drainage. It is important to note that most patients
who developed perforation had1 risk factors reported to be
associated with perforation (older age, low BMI, female sex,
congestive heart failure, non-AF indication, and chronic lung
disease). Familiarity with these risk factors could help selectpatients at lower risk of perforation or allow physicians to
exert an extra effort to avoid the RV apex in these patients.
We observed a total of 144 deaths (7.9%) over the dura-
tion of follow-up. This is on par with the reported mortality
in similar cohorts of patients referred for single lead pace-
maker implantation. For instance, in a study by Pyatt
et al,13 the 1-year mortality in such a cohort wasw20%.Study limitations
This is a prospective registry comparing the outcomes of the
Micra TPS to a historical transvenous pacing cohort
implanted with dual-chamber pacemakers. While we have
excluded complications related to the atrial lead, a compari-
son to a cohort implanted with VVI pacemakers may have
provided a more fair assessment. Furthermore, only a ran-
domized controlled study would allow a direct comparison
and would clearly deﬁne the beneﬁts and drawbacks of lead-
less pacing compared to TV-PPMs. Nevertheless, this regis-
try presents prospective data on the largest cohort of patients
implanted with the Micra TPS.Conclusion
The updated results of the Micra PAR highlight the major
advantages of a leadless pacing system in reducing compli-
cations associated with the pocket and lead of TV-PPMs.
Furthermore, low rates of infections and dislodgments
El-Chami et al Micra Updated Real-World Performance 1807were observed. These results also alleviate some of the
early concerns about perforation rates, showing .50%
reduction in the rate of pericardial effusions compared to
the IDE study.Acknowledgments
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